Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mecapegfilgrastim - Jiangsu Hengrui Medicine Co.

Next Previous
X
Search
Drug Profile

Mecapegfilgrastim - Jiangsu Hengrui Medicine Co.

Alternative Names: HHPG-19K; Pegfilgrastim biosimilar - Jiangsu Hengrui Medicine Co.; Pegylated rhG-CSF - Jiangsu Hengrui Medicine Co.; Tiopefigeristine - Jiangsu Hengrui Medicine Co.

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Amines; Carboxylic acids; Chemoprotectants; Granulocyte colony-stimulating factors; Organic sulfur compounds; Polyethylene glycols; Pyrrolidines; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neutropenia

Most Recent Events

  • 12 Feb 2024 Jiangsu HengRui Medicine plans a phase III trial for Neutropenia (Prevention, Chemotherapy-induced) in China (NCT06254742)
  • 01 Aug 2022 Jiangsu HengRui Medicine initiates a phase II trial for Breast cancer (In adults, In the elderly, Prevention, Chemotherapy induced) in China (NCT05463601)
  • 14 Dec 2021 Jiangsu HengRui Medicine and Sun Yat-sen University plans a clinical trial for Neutropenia in December 2021 (Parenteral) (NCT05156554)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top